PubHawk
JCO Precis Oncol January 2025 PMID 39889245

Digital Pathology-Based Multimodal Artificial Intelligence Scores and Outcomes in a Randomized Phase III Trial in Men With Nonmetastatic Castration-Resistant Prostate Cancer.

Felix Y Feng, Matthew R Smith, Fred Saad, Pooya Mobadersany, Shaozhou K Tian, Stephen S F Yip, Joel Greshock, Najat Khan, Margaret K Yu, Sharon McCarthy, Sabine D Brookman-May, Ariel B Bourla, Tamara Todorovic, Rikiya Yamashita, Huei-Chung Huang

Full text PDF Download social card

Mentions

2
Peak: 1 in Feb 2025
across 2 sources since Feb 2025

Extended reach

5,428
potential audience

Total likes

0

Video views

120

Mentions per month

Feb 2025 – Apr 2025

Where it's discussed

  • X / Twitter1 posts
  • YouTube1 videos

AI synopsis

What people are saying

Discussions consistently praise the innovative use of AI in predicting treatment outcomes, using phrases like 'game-changing' and 'promising approach,' which underscores both interest and perceived impact. The tone emphasizes the potential for improving patient stratification and personalized therapies, reflecting active engagement and support for the study's implications.

AgreementModerate agreement

Most discussions express support for the significance of the AI scoring system and its findings, with some highlighting its potential clinical benefits.

InterestModerate interest

Participants show moderate interest, reflecting curiosity about how digital pathology and AI influence treatment strategies.

EngagementHigh engagement

Many discussions delve into the methodology, implications, and potential for personalized medicine, indicating deep engagement.

ImpactModerate impact

There is a recognition that this research could lead to meaningful improvements in patient outcomes and treatment targeting, suggesting a moderately high impact.

Abstract in brief

  • The study found that a digital AI-based scoring system (MMAI) can predict the outcomes of men with nonmetastatic castration-resistant prostate cancer (nmCRPC), with higher risk scores associated with shorter metastasis-free survival, progression-free survival, and overall survival.
  • Patients classified as high-risk by MMAI showed significant benefits from the addition of apalutamide to their treatment, with improved survival outcomes compared to those not receiving the drug.
  • The interaction between MMAI risk scores and treatment effectiveness suggests that the AI-based marker could help identify patients who are most likely to benefit from targeted therapies like apalutamide.]
Read the full abstract

Top posts

Most liked on X and Bluesky
JCO Precision Oncology
@JCOPO_ASCO · X

Digital Pathology–Based Multimodal Artificial Intelligence Scores and Outcomes in a Randomized Phase III Trial in Men With Nonmetastatic Castration-Resistant Prostate Cancer. #prostatecancer #pcsm Read more: https://t.co/UKRHQLHfCX

Feb 7, 2025 · 5,308 followers View post →

All mentions

JCO Precision Oncology
@JCOPO_ASCO · X

Digital Pathology–Based Multimodal Artificial Intelligence Scores and Outcomes in a Randomized Phase III Trial in Men With Nonmetastatic Castration-Resistant Prostate Cancer. #prostatecancer #pcsm Read more: https://t.co/UKRHQLHfCX

Feb 7, 2025 · 5,308 followers View post →